[HTML] frontiersin.org

[HTML][HTML] Multi-pharmacology of berberine in atherosclerosis and metabolic diseases: potential contribution of gut microbiota

S Yang, D Li, Z Yu, Y Li, M Wu - Frontiers in Pharmacology, 2021 - frontiersin.org
Atherosclerosis (AS), especially atherosclerotic cardiovascular diseases (ASCVDs), and
metabolic diseases (such as diabetes, obesity, dyslipidemia, and nonalcoholic fatty liver …
被引用次数：26 相关文章

Multi-Pharmacology of Berberine in Atherosclerosis and Metabolic Diseases: Potential Contribution of Gut Microbiota.

S Yang, D Li, Z Yu, Y Li, M Wu - Frontiers in Pharmacology, 2021 - europepmc.org
Atherosclerosis (AS), especially atherosclerotic cardiovascular diseases (ASCVDs), and
metabolic diseases (such as diabetes, obesity, dyslipidemia, and nonalcoholic fatty liver …

Multi-pharmacology of berberine in atherosclerosis and metabolic diseases: potential contribution of gut microbiota.

S Yang, D Li, Z Yu, Y Li, M Wu - 2021 - cabidigitallibrary.org
Atherosclerosis (AS), especially atherosclerotic cardiovascular diseases (ASCVDs), and
metabolic diseases (such as diabetes, obesity, dyslipidemia, and nonalcoholic fatty liver …

Multi-Pharmacology of Berberine in Atherosclerosis and Metabolic Diseases: Potential Contribution of Gut Microbiota

S Yang, D Li, Z Yu, Y Li, M Wu - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Atherosclerosis (AS), especially atherosclerotic cardiovascular diseases (ASCVDs), and
metabolic diseases (such as diabetes, obesity, dyslipidemia, and nonalcoholic fatty liver …
[HTML] nih.gov

[HTML][HTML] Multi-Pharmacology of Berberine in Atherosclerosis and Metabolic Diseases: Potential Contribution of Gut Microbiota

S Yang, D Li, Z Yu, Y Li, M Wu - Frontiers in Pharmacology, 2021 - ncbi.nlm.nih.gov
Atherosclerosis (AS), especially atherosclerotic cardiovascular diseases (ASCVDs), and
metabolic diseases (such as diabetes, obesity, dyslipidemia, and nonalcoholic fatty liver …